Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05625386
Other study ID # AHMU-TMS-FOG-twotargets
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date December 22, 2022
Est. completion date March 31, 2024

Study information

Verified date April 2024
Source Anhui Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the current study was to verify whether high-dose TMS treatment of the motor and cognitive cortices is more effective in alleviating FOG than conventional-dose TMS of the motor cortex only. Specifically, investigator hypothesized that the effect of dual-target TMS on FOG is better than traditional stimulation of the motor cortex only, and the effect of high-dose TMS is better than conventional doses.


Description:

This was an open-label, randomized controlled study. Participants were randomized in a 1:1:1 fashion to receive dual-target, high-dose TMS (DHT), dual-target, conventional-dose TMS (DCT), and single-target, conventional-dose TMS (SCT). SCT was designated as the control group with protocol reference to evidence-based guidelines, while DHT and DCT served as the experimental groups. DHT refers to the left primary motor cortex of the lower leg (M1) and dorsolateral prefrontal cortex (DLPFC) receiving 9000 pulses/day of intermittent TBS (iTBS) for 5 consecutive days. DCT refers to the left M1 and DLPFC receiving 1800 pulses/day of iTBS for 5 consecutive days. The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session. SCT refers to the left M1 receiving 1800 pulses/day of iTBS treatment for 5 consecutive days. Motor and cognitive measures were performed ("on medication" state) 1 day before TMS (baseline), 1 day after completion of TMS (post), and 1 month after completion of TMS (follow-up). The primary outcome of this study was the change in FOGQ scores from baseline to follow-up. Secondary outcomes included changes in the Unified Parkinson's Disease Rating Scale Part III (UPDRS III), 5 m Timed Up-and-Go test (TUG), FOG-provoking test (Standing-Start 180° Turn Test, SS-180), Stroop color-naming (SCN), Stroop word-reading (SWR), Stroop color-word (SCW), and Color Trails Test interference index (CTTII) from baseline to follow-up. TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by the participant's anatomical image (1 × 1 × 1 mm3) and a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada). Stimulation intensity: Because each participant had different sensitivity to TMS, the individual Resting Motor Threshold (RMT) was measured before intervention. Specifically, surface electrodes (Ag/AgCl) were attached to both ends of the right abductor pollicis muscle (the ground wire was connected to the ulnar styloid process) and the left finger motor cortex was stimulated one time. The motor-evoked potentials were recorded from the hand muscles. The RMT was considered when the evoked potential > 50 μV occurred in > 5 of 10 consecutive stimulations. The stimulation intensity during intervention was 80% of the RMT in the current study. Stimulation sequence: Each iTBS sequence in the high-dose stimulation sequence released 900 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of 10 iTBS sessions was performed each day with an interval of 40 min and the daily stimulation dose was 9000 pulses. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses. Stimulation targets: There were two stimulation targets in this study that were used to intervene in the motor and cognitive cortices. The stimulation target of the motor cortex is located in the lower leg of the left primary motor cortex in the Montreal Neurological Institute space (coordinates: -10, -24, 75 [https:/ /afni.nimh.nih.gov/MNI_Atlas]) based on structural MRI. The stimulation target of the cognitive cortex was the left dorsolateral prefrontal cortex, which has the strongest functional connectivity with the executive control network (see Supplementary materials), based on fMRI. Finally, targets were transformed into the native space for each participant by applying an inverse matrix produced during brain structure and function segmentation using SPM12 (www.fil.ion.ucl.ac.uk/spm) and TMStarget software.


Recruitment information / eligibility

Status Terminated
Enrollment 64
Est. completion date March 31, 2024
Est. primary completion date February 25, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria: 1. diagnosis of FOG with expertise in movement disorders. 2. the score of item 3 of the FOG questionnaire =1. 3. ongoing treatment with a stable dose of any medication for 2 months. 4. 40 years of age or older. Exclusion Criteria: 1. a history of addiction, psychiatric disorders, or neurological diseases other than PD. 2. focal brain lesions on T1-/T2-weighted fluid-attenuated inversion recovery images. 3. anti-PD medication adjustments during rTMS treatment. 4. history of substance abuse within the past 6 months. 5. nonremovable metal objects in or around the head. 6. previously received rTMS treatment. 7. prior history of seizure or history in first-degree relatives.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
transcranial magnetic stimulation
TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).

Locations

Country Name City State
China Cognitive Neuropsychology Lab Anhui Medical University Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
Anhui Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Freezing of Gait Questionnaire (FOGQ) scores This is an very common clinical motor estimating scale for evaluating FOG. 6 items and each item scored between 0 and 4 points (24 scores in total). Higher scores mean a worse outcome the changes in FOGQ scores from baseline to 1 month after completion of TMS (follow-up).
Secondary The timed up and go test (TUG) The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box .The time during the whole course are measured. The time is recorded in seconds, and the longer the time, the more severe the symptoms.The longer it takes, the worse it gets changes from baseline to 1 month after completion of TMS (follow-up).
Secondary Unified Parkinson's Disease Rating Scale III (UPDRSIII) scores This is an very common clinical motor estimating scale, 14 items and 108' in total. Higher scores indicate worse symptoms. Higher scores mean a worse outcome. changes from baseline to 1 month after completion of TMS (follow-up).
Secondary Stroop test stroop color word test is generally divided into three parts: (1) Quick naming of color dot plots (SCN); (2) Recite the nouns representing the color names quickly (SWR); (3) Present a set of cards, in which the nouns representing the color names are written on the cards in different colors, and check the ability of the subjects to distinguish between the color names and the actual colors, as well as the ability to recite the nouns representing the color names quickly (SCW). The degree to which subjects were influenced by font color as an indicator (SCW) of their cognitive control. The longer it takes, the worse it gets. changes (SCN, SWR, SCW) from baseline to 1 month after completion of TMS (follow-up).
Secondary Color Trails Test interference index (CTTII) The number color connection test was divided into two parts, A and B. Part A asked the subjects to connect 25 numbers on the paper in order. In Part B, numbers and letters were replaced by numbers of two different colors to eliminate the influence of culture on the test. When the subjects were asked to connect numbers in order, the two graphs were arranged alternately. The measurement index was time, and the longer the time, the more obvious the decline in prompt ability. CTTII=CTT(part B)-CTT(part A). The longer it takes, the worse it gets. changes rom baseline to 1 month after completion of TMS (follow-up).
Secondary The Standing-Start 180° Turn Test (SS-180) The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box.The time during the 180° turn (SS180) are measured. The time is recorded in seconds, and the longer the time, the more severe the symptoms. The longer it takes, the worse it gets. changes from baseline to 1 month after completion of TMS (follow-up).
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04927364 - Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder N/A
Recruiting NCT05973019 - rTMS Improves Functions in Spinocerebellar Ataxia N/A
Recruiting NCT06193278 - Individual Neuromodulation for PDS N/A
Completed NCT05074524 - Repetitive Transcranial Magnetic Stimulation to Reduce Heroin Cravings N/A
Recruiting NCT05889117 - Brain Stimulation for Concussion N/A
Recruiting NCT03974659 - Enhanced Recovery After Surgery Using TMS on Cerebellar Language Area for Brain Tumor Patients N/A
Recruiting NCT05613686 - Theta Burst Stimulation for Motor Recovery N/A
Completed NCT04014491 - The Effects of Exercise Training on Corticospinal System in Overhead Athletes With Shoulder Impingement Syndrome N/A
Recruiting NCT05914038 - Individualized rTMS for Motor Recovery in Stroke Patients N/A
Recruiting NCT06084455 - TMS-evoked Potentials During Aerobic Exercise N/A
Completed NCT05566444 - TMS-evoked Potentials During Heat Pain N/A
Enrolling by invitation NCT04313530 - TMS Treatment in Multiple System Atrophy With Fatigue N/A
Completed NCT04209309 - Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal N/A
Terminated NCT04486222 - Accelerated Bilateral rTMS on Geriatric Depression N/A
Recruiting NCT05192759 - Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait N/A
Recruiting NCT05467657 - Transcranial Magnetic Stimulation on Somtosensory Cortex Enhances Motor Learning in People With Stroke N/A
Recruiting NCT05896332 - rTMS in Older Adults With MCI and AUD Phase 1
Recruiting NCT04727177 - Precision-targeted Transcranial Magnetic Stimulation in the Treatment of Primary Dystonia Early Phase 1
Recruiting NCT04906603 - Theta Burst Stimulation for Headaches After Traumatic Brain Injury N/A
Recruiting NCT03590327 - Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment N/A